People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants, according to a news release issued by Johnson & Johnson.

Spravato is a ketamine-derived nasal spray that is FDA-approved for treatment-resistant depression. The Johnson & Johnson drug has been on the market since 2019, but could only be prescribed ...